congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
Joyce O’Shaughnessy
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
An open-label, interventional, multicenter study of trastuzumab deruxtecan monotherapy in patients with unresectable and/or metastatic HER2-low or HER2 immunohistochemistry 0 breast cancer: DESTINY-Breast15
Shanu Modi
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Breast Cancer
Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe
Peter S. Hall
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
Blocking soluble TNF to improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model
Sofia Bruni
Poster
Dato-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
Durvalumab + datopotamab deruxtecan in patients with PD-L1–positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open-label, platform BEGONIA study
Peter Schmid
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: First interim analysis of EUROPA T-DXd
Michelino De Laurentiis
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
Exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with advanced/metastatic HER2+ breast cancer: Analyses from phase 3 studies DESTINY-Breast02 and DESTINY-Breast03
Claire Li
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Breast Cancer
Patient characteristics and treatment sequencing among HER2-low metastatic breast cancer patients with rapid vs delayed progression on first-line endocrine therapy
Chia Jie Tan
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Breast Cancer
Patient preferences for HR+/HER2- metastatic breast cancer treatments in Italy: A qualitative assessment
Grazia Arpino
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer subjects: Analyses across twelve phase 1-3 studies
Claire Li
Pages: 1  2  

footer